{
    "1650847246991147008": {
        "attachments": {
            "media_keys": [
                "13_1650847200598020098"
            ]
        },
        "author_id": "62465691",
        "created_at": "2023-04-25T13:00:29.000Z",
        "edit_history_tweet_ids": [
            "1650847246991147008"
        ],
        "entities": {
            "annotations": [
                {
                    "end": 24,
                    "normalized_text": "Transthyretin amyloidosis",
                    "probability": 0.9035,
                    "start": 0,
                    "type": "Other"
                },
                {
                    "end": 30,
                    "normalized_text": "ATTR",
                    "probability": 0.4955,
                    "start": 27,
                    "type": "Other"
                },
                {
                    "end": 99,
                    "normalized_text": "amyloid",
                    "probability": 0.5729,
                    "start": 93,
                    "type": "Other"
                },
                {
                    "end": 183,
                    "normalized_text": "ATTR",
                    "probability": 0.6376,
                    "start": 180,
                    "type": "Other"
                },
                {
                    "end": 253,
                    "normalized_text": "AAN2023",
                    "probability": 0.5635,
                    "start": 247,
                    "type": "Other"
                }
            ],
            "hashtags": [
                {
                    "end": 254,
                    "start": 246,
                    "tag": "AAN2023"
                }
            ],
            "urls": [
                {
                    "display_url": "spr.ly/6013OuByz",
                    "end": 278,
                    "expanded_url": "http://spr.ly/6013OuByz",
                    "start": 255,
                    "status": 200,
                    "unwound_url": "https://www.astrazeneca.com/media-centre/articles/2022/raising-awareness-attr.html?utm_source=twitter&utm_medium=aan+-+american+academy+of+neurology&utm_term=11796&utm_content=cvrm",
                    "url": "https://t.co/8NqOxyWgAu"
                },
                {
                    "display_url": "pic.twitter.com/5qXBi8pgyv",
                    "end": 302,
                    "expanded_url": "https://twitter.com/AstraZeneca/status/1650847246991147008/video/1",
                    "media_key": "13_1650847200598020098",
                    "start": 279,
                    "url": "https://t.co/5qXBi8pgyv"
                }
            ]
        },
        "id": "1650847246991147008",
        "lang": "en",
        "public_metrics": {
            "bookmark_count": 0,
            "impression_count": 4960,
            "like_count": 17,
            "quote_count": 0,
            "reply_count": 6,
            "retweet_count": 5
        },
        "text": "Transthyretin amyloidosis (ATTR) is a progressive disease caused by the buildup of misfolded amyloid fibrils in organs and tissues. We're committed to advancing the science behind ATTR because it interferes with the normal functions of the body. #AAN2023 https://t.co/8NqOxyWgAu https://t.co/5qXBi8pgyv"
    }
}